All Stories

  1. Author's reply: “Anti-parietal cell antibodies are more prevalent and clinically relevant in autoimmune endocrine diseases: Comment on the ARIOSO position paper”
  2. Concomitant Assessment of Oral and Gastric Microbiota Composition in Autoimmune Gastritis Patients: A Case–Control Study
  3. Intramuscular Cyanocobalamin Treatment in Patients with Corpus Atrophic Gastritis and Vitamin B12 Deficiency: Efficacy and Predictors of Increased Requirement—A Monocentric Longitudinal Real-Life Cohort Study
  4. Helicobacter pylori multiplex serology in patients with autoimmune atrophic gastritis negative for Helicobacter pylori at histology: A case-control study
  5. Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study
  6. Autoimmune gastritis: Diagnosis, clinical management and natural history. A position paper by the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)
  7. The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm
  8. Chronic atrophic gastritis and dyspepsia: a forgotten link?
  9. Letter to the Editor
  10. Bile acid diarrhea in patients with chronic diarrhea. Current appraisal and recommendations for clinical practice
  11. Antral mucosa healing at long-term follow-up in patients with corpus atrophic gastritis and concomitant antral gastritis may mimic autoimmune gastritis
  12. Look inside the management of colonic diverticular rebleeding: a systematic review
  13. The Diagnosis and Management of Chronic Constipation in Italy: Results from a Survey Conducted among Italian Gastroenterologists
  14. Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
  15. Sarcopenia in Patients with Advanced Gastrointestinal Well-Differentiated Neuroendocrine Tumors
  16. Symptomatic uncomplicated diverticular disease: a critical appraisal
  17. Convolutional Neural Network Model for Intestinal Metaplasia Recognition in Gastric Corpus Using Endoscopic Image Patches
  18. Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?
  19. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis
  20. Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection
  21. Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
  22. Endoscopic management of gastric, duodenal and rectal NETs: Position paper from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED)
  23. Systematic review and meta‐analysis: Risk of gastric cancer in patients with first‐degree relatives with gastric cancer
  24. Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study
  25. Common Diagnostic Challenges and Pitfalls in Segmental Colitis Associated with Diverticulosis (SCAD)
  26. Gastric Microbiota Gender Differences in Subjects with Healthy Stomachs and Autoimmune Atrophic Gastritis
  27. Comparison of Clinical, Biochemical and Histological Features between Adult Celiac Patients with High and Low Anti-Transglutaminase IgA Titer at Diagnosis and Follow-Up
  28. Patients with Diverticular Disease Have Different Dietary Habits Compared to Control Subjects: Results from an Observational Italian Study
  29. Sex–Gender Differences in Adult Coeliac Disease at Diagnosis and Gluten-Free-Diet Follow-Up
  30. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
  31. Prevalence of Segmental Colitis Associated with Colonic Diverticulosis in a Prospective Cohort of Patients Who Underwent Colonoscopy in a Tertiary Center
  32. Editorial: lymphocytic gastritis and its relationships with other gastrointestinal disorders
  33. Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics
  34. Role of Dietary Habits in the Prevention of Diverticular Disease Complications: A Systematic Review
  35. Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review
  36. Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database
  37. Diagnostic Accuracy of EndoFaster® and Narrow-Band Imaging Endoscopy in Patients with Impaired Gastric Acid Secretion: A Real-Time Prospective Study
  38. Relationship between Persistent Gastrointestinal Symptoms and Duodenal Histological Findings after Adequate Gluten-Free Diet: A Gray Area of Celiac Disease Management in Adult Patients
  39. Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach
  40. Autoimmune Gastritis and Gastric Microbiota
  41. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy
  42. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs
  43. SARS-CoV2 RNA detection in a pancreatic pseudocyst sample
  44. The Trends of Complicated Acute Colonic Diverticulitis—A Systematic Review of the National Administrative Databases
  45. Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study
  46. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian...
  47. Occurrence of Acute Oesophageal Necrosis (Black Oesophagus) in a Single Tertiary Centre
  48. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  49. Do Alterations in Bone Mineral Density Go Beyond Borders in Adults With Celiac Disease?
  50. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  51. A single vial is enough in the absence of endoscopic suspected intestinal metaplasia – less is more!
  52. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study
  53. Treatment of diverticular disease, targeting symptoms or underlying mechanisms
  54. Risk Factors Associated with the Occurrence of Autoimmune Diseases in Adult Coeliac Patients
  55. Recent advances in understanding and managing diverticulitis
  56. Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry
  57. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE)
  58. Diverticular disease: myths and facts
  59. Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country
  60. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review
  61. Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients
  62. Upper gastrointestinal symptoms in autoimmune gastritis
  63. Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population
  64. Role of endoscopic surveillance for intestinal metaplasia limited to the antrum
  65. Italian Guidelines
  66. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate
  67. Gastric precancerous conditions andHelicobacter pyloriinfection in dyspeptic patients with or without endoscopic lesions
  68. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions
  69. Letter: gastric cancer and pernicious anaemia - only a minority of UK pernicious anaemia patients have had a gastroscopy - authors’ reply
  70. A case of Barrett’s oesophagus in pernicious anaemia: acid is not the only culprit!
  71. Pernicious Anemia: Time to Justify Endoscopic Monitoring?
  72. Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging
  73. Probiotics and Diverticular Disease
  74. Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease
  75. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015
  76. ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study
  77. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines
  78. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC)
  79. Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia
  80. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up
  81. E-cadherin germline mutation carriers: clinical management and genetic implications
  82. Updated features associated with type 1 gastric carcinoids patients: a single-center study
  83. Editorial: mucosal healing and adherence to the gluten-free diet in coeliac disease - authors' reply
  84. Prevalence of lesions detected at upper endoscopy: An Italian survey
  85. Detection of Gastric Precancerous Conditions in Daily Clinical Practice: A Nationwide Survey
  86. Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study
  87. Italian consensus conference for colonic diverticulosis and diverticular disease
  88. Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease
  89. Gastric cancer in patients with type I gastric carcinoids
  90. Are clinical features able to predict Helicobacter pylori gastritis patterns? Evidence from tertiary centers
  91. Proton pump inhibitor therapy and potential long-term harm
  92. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge
  93. Helicobacter pyloriinfection and drugs malabsorption
  94. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome
  95. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders
  96. Letter: gastric cancer and pernicious anaemia - oftenHelicobacter pyloriin disguise; authors' reply
  97. Intestinal metaplasia surveillance: Searching for the road-map
  98. Systematic review: gastric cancer incidence in pernicious anaemia
  99. No higher risk for colorectal cancer in atrophic gastritis-related hypergastrinemia
  100. Appropriateness of the Indication for Colonoscopy
  101. Chronic Idiophatic Urticaria and Helicobacter Pylori: A Specific Pattern of Gastritis and Urticaria Remission after Helicobacter Pylori Eradication
  102. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey
  103. Micronutrients (Other than iron) and Helicobacter pylori Infection: A Systematic Review
  104. High-fibre diet andLactobacillus paracasei B21060in symptomatic uncomplicated diverticular disease
  105. Is proliferative colonic disease presentation changing?
  106. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal
  107. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate
  108. Role of gastritis pattern on Helicobacter pylori eradication
  109. Treatment of Diverticular Disease of the Colon and Prevention of Acute Diverticulitis: A Systematic Review
  110. Diagnosis and Management of Pernicious Anemia
  111. Development of type I gastric carcinoid in patients with chronic atrophic gastritis
  112. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
  113. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer
  114. HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population
  115. Low prevalence of idiopathic peptic ulcer disease: An Italian endoscopic survey
  116. Cost-effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia
  117. Helicobacter pyloriimmunoproteomics in gastric cancer and gastritis of the carcinoma phenotype
  118. Appropriateness of the indication for upper endoscopy: A meta-analysis
  119. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis
  120. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy
  121. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis
  122. Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency
  123. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy
  124. Systematic review:Heliocobacter pyloriinfection and impaired drug absorption
  125. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
  126. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy
  127. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
  128. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography
  129. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation
  130. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
  131. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
  132. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations
  133. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide
  134. Pernicious anemia: New insights from a gastroenterological point of view
  135. Pre-endoscopic screening for Helicobacter pylori and celiac disease in young anemic women
  136. Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia
  137. A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors
  138. The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI)
  139. Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis
  140. Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis
  141. Assessing the severity of atrophic gastritis
  142. Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis?
  143. After Helicobacter pylori, Genetic Susceptibility to Gastric Carcinoma Revisited
  144. Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction
  145. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease
  146. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients
  147. Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease
  148. CagA and VacA are Immunoblot Markers of Past Helicobacter pylori Infection in Atrophic Body Gastritis
  149. Corpus-predominant gastritis as a risk factor for false-negative13C-urea breath test results
  150. Thyroxine in Goiter, H. pylori Infection, and Gastritis
  151. Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis
  152. Unawareness of gastrointestinal symptomatology in adult coeliac patients with unexplained iron-deficiency anaemia presentation
  153. Western Blotting of Total Lysate of Helicobacter pylori in Cases of Atrophic Body Gastritis
  154. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection
  155. Of Bacteria, Acid, and Blood
  156. Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up
  157. Early Manifestations of Gastric Autoimmunity in Patients with Juvenile Autoimmune Thyroid Diseases
  158. Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis ofHelicobacter PyloriInfection in Patients with Atrophic Body Gastritis
  159. Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis
  160. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment
  161. Gastric Neuroendocrine Tumors
  162. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors
  163. Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy
  164. IS ENDOSCOPY WORTHWHILE IN MENSTRUATING FEMALES WITH IRON DEFICIENCY?
  165. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract
  166. DXA vs. QCT for subclinical celiac disease patients
  167. Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis
  168. Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome
  169. Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia
  170. The stomach and iron deficiency anaemia: a forgotten link
  171. Antibiotic Prophylaxis of Bacterial Infections in Cirrhotic Inpatients: a Meta-Analysis of Randomized Controlled Trials
  172. Timing and sampling in surveillance of premalignant gastric lesions
  173. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis
  174. Consequences of Helicobacter pylori infection on the absorption of micronutrients
  175. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas
  176. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients
  177. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment
  178. Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease
  179. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid
  180. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection
  181. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?
  182. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms
  183. Two-thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection
  184. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection
  185. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: When should it be done?
  186. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients
  187. Iron deficiency anaemia and Helicobacter pylori infection
  188. Role of Helicobacter pylori infection in pernicious anaemia
  189. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia
  190. Long-term octreotide treatment of metastatic carcinoid tumor
  191. Duodenal Ulcer Relapse Is Not Always Associated with Recurrence of H. pylori Infection: A Prospective Three-Year Follow-Up Study
  192. Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study
  193. Correspondence
  194. Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease
  195. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia A prospective screening study
  196. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases
  197. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
  198. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs
  199. Atrophic Body Gastritis: Distinct Features Associated with Helicobacter pylori Infection
  200. Reversal of Long-Standing Iron Deficiency Anaemia after Eradication ofHelicobacter pyloriInfection
  201. Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study
  202. Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia
  203. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth
  204. Somatostatin Receptor Localization of Pancreatic Endocrine Tumors
  205. Modulation of Growth of Human Gastric Enterochromaffin-Like Cells
  206. Effects of Recent, Short-Term Hyperglycemia on Responses to Hypoglycemia in Humans: Relevance to the Pathogenesis of Hypoglycemia Unawareness and Hyperglycemia-Induced Insulin Resistance
  207. Erratum
  208. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM
  209. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans
  210. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin a production by intestinal lamina propria lymphocytes
  211. Helicobacter pylori Infection in Children with Antral Gastrin Cell Hyperfunction
  212. Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity
  213. Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM
  214. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide
  215. Maintenance Treatment with H2 Receptor Antagonists for Duodenal Ulcer Disease: Toward a Rational Use
  216. Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger?Ellison syndrome during omeprazole treatment
  217. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity
  218. Gut neuropeptides and the immune system
  219. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation
  220. Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy
  221. Effect of Vasoactive Intestinal Peptide Neuropeptide on Natural Killer Activity from Peripheral Blood Lymphocytes of Normal Subjects
  222. Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans
  223. Modulatory Effects of Somatostatin and Vasoactive Intestinal Peptide on Human Intestinal Lymphocytes
  224. Medical Treatment of Antral Gastrin Cell Hyperfunction: Role of Nonantisecretory Therapy
  225. Somatostatin Infused during Acute Pancreatitis Retains Its Biological Activity
  226. Loss of Efficacy of Famotidine in the Control of Gastric Acid Secretion in Patients with Zollinger-Ellison Syndrome Reversed by Omeprazole
  227. HYPERGASTRINAEMIA AFTER LONG-TERM H2-BLOCKER TREATMENT
  228. Pancreatic polypeptide response to a protein-rich meal in diabetic patients with and without neuropathy
  229. Gastric acid and pancreatic polypeptide responses to modified sham feeding: indication of an increased basal vagal tone in a subgroup of duodenal ulcer patients.
  230. Evidence that bombesin releases extragastric gastrin in man
  231. Bombesin effects on human GI functions
  232. Peptides of the APUD system in amphibian skins
  233. Bombesin, Trypsin, and Chronic Pancreatitis
  234. Effect of Bombesin on Plasma Insulin, Pancreatic Glucagon, and Gut Glucagon in Man*
  235. NEUROTENSIN AND THE DUMPING SYNDROME